CombiMatrix Registers to Exercise Warrants; Could Net up to $19.5M | GenomeWeb
NEW YORK (GenomeWeb News) – CombiMatrix yesterday registered with the US Securities and Exchange Commission to sell up to 2,305,274 shares upon the exercise of outstanding warrants.
The company said in its SEC filing that if all of the warrants are exercised, it will net up to $19,510,926 before deducting around $17,500 in expenses.
CombiMatrix said it intends to use the proceeds for working capital, research and development, general and administrative expenses, and sales and marketing activities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.